Yousef Moradi | Epidemiology | Best Researcher Award

Published on by Health Scientists

Assist. Prof. Dr. Yousef Moradi | Epidemiology | Best Researcher Award

Epidemiologist | Kurdistan University | Iran

Dr. Yousef Moradi is an accomplished researcher and academic whose work spans epidemiology, public health, and biomedical sciences, reflecting a sustained commitment to advancing scientific knowledge and improving population health outcomes. His expertise integrates communicable and non-communicable disease epidemiology, health inequalities, infectious disease surveillance, molecular and clinical research, and advanced evidence-synthesis methodologies. He has authored an extensive body of peer-reviewed publications and earned broad scholarly recognition through citations, editorial contributions, and active peer-review involvement with reputable international journals. Dr. Moradi’s research collaborations extend across multidisciplinary teams, national health authorities, and global agencies, contributing to policy-relevant studies, community-centered interventions, and high-impact investigations focused on vulnerable and high-risk populations. His work has informed health service delivery, strengthened public health programs, refined national guidelines, and generated actionable insights for health system improvement. He has also contributed meaningfully to academic environments through postgraduate teaching, thesis supervision, professional development activities, and curriculum enhancement, fostering a culture of scientific rigor and student achievement. His leadership in research design, data analytics, field implementation, and interdisciplinary coordination supports evidence-based decision-making and the development of informed health policies. With a strong record of contribution to global scientific discourse, a commitment to ethical and equity-driven research, and active engagement in collaborative investigations, Dr. Yousef Moradi continues to advance public health knowledge, address emerging health challenges, and promote socially responsive, evidence-informed solutions with lasting societal impact. He has 19639 citations from 233 documents with an h-index of 39.

Profiles: Google Scholar | Scopus | ORCID

Publications

1. Ghadirzadeh, B., Afshar, M., Afraie, M., Moradveisi, B., & Moradi, Y. (2025). Efficacy of zinc sulfate supplementation in managing neonatal hyperbilirubinemia: A meta-analysis. The Journal of Maternal-Fetal & Neonatal Medicine.

2. Ouyang, F., Hu, W., Reisman, J., Pogoda, T. K., Carlson, K. F., Liu, W., Moradi, Y., & colleagues. (2025). Association between PTSD and health-related social needs in US Veterans: An NLP analysis using Veterans Health Administration data. Journal of Affective Disorders.

3. Mestrovic, T., Naghavi, M., Aguilar, G. R., Weaver, N. D., Swetschinski, L. R., & colleagues. (2025). The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: A cross-country systematic analysis with forecasts to 2050. The Lancet Public Health.

4. Ghaderkhanzadeh, H., Asadi, J., Hemmati, Z., Saed, L., Nouri, E., & Moradi, Y. (2025). The role of thyroid autoimmunity in assisted reproductive techniques outcomes: An updated comprehensive meta-analysis. Clinical and Experimental Obstetrics & Gynecology.

5. Rahimi, M., Haghighi, L., Majidnia, M., Ghadirzadeh, B., & Moradi, Y. (2025). Diagnostic performance of PAPP-A and β-hCG in early detection of gestational diabetes mellitus: A meta-analysis. Acta Diabetologica.

Duo Liu | Epidemiology | Best Researcher Award

Published on by Health Scientists

Prof. Duo Liu | Epidemiology | Best Researcher Award 

Deputy Director, Department of Clinical Pharmacy | Harbin Medical University | China

Professor Duo Liu, Chief Pharmacist and Doctoral Supervisor at Harbin Medical University Cancer Hospital, is a distinguished pharmaceutical scientist whose research has significantly advanced the fields of pharmacogenomics, pharmacoepidemiology, and precision oncology. With a strong background in medical genetics and pharmacology, Professor Liu has developed a research portfolio that bridges molecular pharmacology with clinical translation, focusing on the genetic mechanisms underlying cancer susceptibility, therapeutic response, and drug resistance. His pioneering contributions include transcriptome-wide association studies identifying novel genetic determinants of pancreatic and prostate cancer risk, as well as investigations into the role of NADPH oxidase polymorphisms and oxidative stress in tumor biology and treatment outcomes. Professor Liu’s scholarly work, published in leading international journals such as Cancer Research, Carcinogenesis, and International Journal of Cancer, has garnered wide recognition for its methodological rigor and clinical relevance. He has successfully led multiple national and institutional research grants, including projects supported by the National Natural Science Foundation of China, and has been honored with several prestigious distinctions for excellence in pharmaceutical sciences and young investigator achievements. As an active member of numerous professional societies, including the Chinese Pharmacological Society and the Anti-Cancer Association of China, Professor Liu contributes to shaping the evolving landscape of cancer pharmacotherapy and drug epidemiology. His collaborations with global research institutions, notably the University of Hawaii Cancer Center, underscore his commitment to advancing international scientific exchange and translational medicine. Through his leadership in clinical pharmacy and mentorship of emerging scientists, Professor Liu continues to drive innovation in personalized cancer treatment and rational drug use, promoting evidence-based healthcare practices that enhance patient outcomes and public health impact worldwide.

Profile: ORCID 

Publications

1. Chen, C., Dong, Q., Wang, H., Dong, S., Wang, S., Lin, W., Jia, C., Dong, M., Jin, Y., & Liu, D. (2025, January 8). The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients. Annals of Hematology.

2. Wang, S. F., Dong, S. Q., Dong, Q., Lin, W. X., Dong, M., & Liu, D. (2024). Natural product-induced oxidative stress-synergistic anti-tumor effects of chemotherapeutic agents. Traditional Medicine Research.

3. Dong, S., Chen, C., Di, C., Wang, S., Dong, Q., Lin, W., & Liu, D. (2024, December). The association between NADPH oxidase 2 (NOX2) and drug resistance in cancer. Current Cancer Drug Targets.

4. Liu, D., Bae, Y. E., Zhu, J., Zhang, Z., Sun, Y., Deng, Y., Wu, C., & Wu, L. (2023, December 15). Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk. Carcinogenesis.

5. Liu, D., Zhao, T., Zhu, J., Sharapov, S., Tiys, E., & Wu, L. (2023, December 4). Associations between genetically predicted plasma N-glycans and pancreatic cancer risk. All Life.